tbuckley/cabot-search huggingface dataset:
1664P Early integration of psycho-oncology in cancer care: A model of care from a quaternary care government hospital in India and its patient related outcomes
Authors: N. Bisht, S. Singh, R. Govind, A. Kapoor, A. Sarin, M. Biju, P. Jaiswal, R. Dhingra, P. Vats
Journal: Annals of Oncology (2024)
1622P A phase II study of the first-in-class oral innate immune activator BXCL701 with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC): Long-term follow-up
Authors: R. Aggarwal, S.T. Tagawa, P. Monk, X. Zhu, R.J. Jones, M. Linch, D. Costin, J.S. de Bono, L.I. Karsh, D.P. Petrylak, P. Borderies, R. Deshpande, V. O'Neill, J. Zhang
Journal: Annals of Oncology (2024)
1703P Updated overall survival in patients with prior checkpoint inhibitor (CPI) therapy in the phase III TIVO-3 study
Authors: M. Zugman, D.F. McDermott, B. Escudier, T.E. Hutson, C.G. Porta, E. Verzoni, M.B. Atkins, B.I. Rini, S.K. Pal
Journal: Annals of Oncology (2024)
1671P Impact of online delivery of potentially sensitive test results on patients with breast cancer's emotional health
Authors: A.C.R.D.C. Ferrari, M.S. Mano, A.K. Shimada, T.K. Takahashi, M. Zanetti, M. Cruz, D. Nakazato, T. Giollo Rivelli, N.M. Fraile, P.H. Mendes Figueiredo, A.L. Perina, A.B.D.S. Fede, A.C. Muhlberger, C.B. Assumpcao, M. Soares, S.K. Loose, G.H. Munhoz Piotto, R. Arakelian, M. Pina
Journal: Annals of Oncology (2024)
1608P Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Authors: M.S. Hofman, A. Gafita, M. Bressel, R. Alipour, S. Levy, L. Emmett, A.S. Ravi Kumar, A.A. Hamid, J.P. Buteau, P.H. Kuo, D.L. Chen, T.A. Hope, A.J. Armstrong, H.I. Scher, H. Schoder, S.K. Sandhu, M.J. Morris
Journal: Annals of Oncology (2024)
1620P Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216)
Authors: S.A. Ingles, J. Pinski, Z. Manojlovic, S. Xiong, D. Weisenberger, A. Goldkorn, C. Tangen, D. McConkey, P.N. Lara, M. Hussain, D.I. Quinn, I.M. Thompson, S. Lerner, T.B. Dorff, N. Agarwal
Journal: Annals of Oncology (2024)
1616P Circulating tumour DNA (ctDNA) measurements and PET-imaging to evaluate response in a phase Ib trial of metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177-PSMA-617 (LuPSMA) plus pembrolizumab (PRINCE)
Authors: S.H. Tolmeijer, E.M. Kwan, S.W.S. Ng, A. Joshua, L. Emmett, M. Crumbaker, A.A. Hamid, A. Anton, L.G. Horvath, J. Chan, M. Bressel, J.P. Buteau, N. Dhiantravan, N. Ayati, S. Keerthikumar, D. Goode, R. Hicks, M.S. Hofman, A.W. Wyatt, S.K. Sandhu
Journal: Annals of Oncology (2024)
1655P Association of location of BRCA1/2 pathogenic variants with benefit from PARP-inhibitors in metastatic castration-resistant prostate cancers: Results from the PROGRESS study
Authors: L. Incorvaia, M. Maruzzo, U. Basso, L. Antonuzzo, M. Rizzo, V. Conteduca, C. Messina, S. Bracarda, G. Mammone, S. Scagliarini, B.A. Maiorano, M. Santoni, G. Facchini, H. Lipari, L. Formisano, U. Malapelle, T.D. Bazan Russo, M. Puglisi, V. Bazan, A. Russo
Journal: Annals of Oncology (2024)
1659TiP A phase I, first-in-human, open-label, multicenter, trial-in-progress of the safety, tolerability, and preliminary efficacy of JNJ-87189401 (PSMA-CD28 bispecific antibody) combined with JNJ-78278343 (KLK2-CD3 bispecific antibody) for advanced prostate cancer
Authors: M.N. Stein, L.S. Graham, C. Baldini, A. Vinceneux, E. Kessler, K. Runcie, A.Z. Wei, K.P. Papadopoulos, A. Bernard-Tessier, M. Laurent, P. Jaiprasart, D. Thaper, F. Shen, L. Cartee, E. Attiyeh, V.M. Villalobos, D. Rasco
Journal: Annals of Oncology (2024)
1658TiP The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) starting androgen deprivation therapy (ADT)
Authors: M. Padden-Modi, H. Abdel-Aty, C. Jones, L.C. Brown, P. Dutey-Magni, Y. Yogeswaran, A. Horsey, C.L. Amos, I. Murray, N. Hujairi, N. Tunariu, R. Millman, W. Cross, V. Kasivisvanathan, M.K. Parmar, N. Clarke, S. Gillessen, G. Attard, C. Parker, N.D. James
Journal: Annals of Oncology (2024)
1643P Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC)
Authors: B. Thapa, N. Henderson, S.T. Tagawa, C. Hwang, A.O. Sokolova, M.A. Bilen, P.M. Coelho Barata, C.B. Nguyen, A. Tripathi, A. Ayanambakkam, L.S. Graham, Y. Zakharia, V.S. Koshkin, E. Heath, T.B. Dorff, A.J. Armstrong, R.R. McKay, A.S. Alva, M. Schweizer, D. Kilari
Journal: Annals of Oncology (2024)
1645P Tumour suppressor gene signature predicts early progression in metastatic hormone-sensitive metastatic prostate cancer (mHSPC) patients
Authors: M. Garcia De Herreros, N. Jimenez Blasco, O. Reig Torras, L. Ferrer Mileo, C. Aversa, S. García-Esteve, L. Rodríguez-Carunchio, I. Trias Puigsureda, J. Padrosa, L. Fernández Mañas, M. Marin, A. Font Pous, A. Rodriguez-Vida, M.A. Climent Duran, S. Cros Costa, I. Chirivella Gonzalez, M. Figols Gorina, B. Mellado Gonzalez
Journal: Annals of Oncology (2024)
1666P Impact of substance use and mental health disorders on cancer care in urban underserved communities
Authors: E. Choi, G. Garcia, A. Gvajaia, M. Imeh, M. Nam, M. El Zein, H.Y.H. Chan, K.K. Anne, M. Altamirano, R. Tariq, R. Llerena Benites, L. Boettner, M. Begolli, M. Muppidi, V. Menon
Journal: Annals of Oncology (2024)
1638P Enzalutamide (enza) with or without leuprolide in patients (pts) with high-risk biochemically recurrent (hrBCR) prostate cancer (PC): EMBARK post hoc analysis by age
Authors: N.D. Shore, U. De Giorgi, M.E. Gleave, M. Kalac, Y. Tang, R. Croitoru, M. Rosales, M. Huynh, T. Tammela, I. Jan de Jong, C. Evans, F.M. Carcano, S.J. Freedland
Journal: Annals of Oncology (2024)
1636P Health-related quality of life outcomes of androgen receptor pathway inhibitors versus taxanes versus standard of care in metastatic castration-resistant prostate cancer: Results from the ProBio trial
Authors: R. Bultijnck, M.H. Strijbos, A. Mortezavi, J. Lindberg, A. Discacciati, C.T. Karlsson, A. Ullén, E. Jänes, G. Enblad, J. Oldenburg, B. Sautois, M.E. Hjälm-Eriksson, H. Sagstuen Haugnes, P. Schatteman, C. Ghysel, B. De Laere, M. Eklund, H. Grönberg, P. Ost, A. Crippa
Journal: Annals of Oncology (2024)
1633P Phase III study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): TALAPRO-2 (TP-2) China cohort
Authors: H. Zeng, D. Ye, H. Guo, Y. Yang, B. Xue, X. Zhang, W. Xiao, J. Jiang, T. Sun, W. Chen, Y. Wang, B. Wan, D. He, Q. Zhang, H. Luo, X. Wang, J. Guo, H. Ye, H. Zhao, Y. Zhang
Journal: Annals of Oncology (2024)
1687P Perceptions of genetic testing and lived experiences in women with locally advanced or metastatic ovarian cancer: A focus on BRCAm and BRCAwt patients
Authors: M.J. Rubio Pérez, A.B. Sanchez, C. Maximiano Alonso, Y. Garcia Garcia, N. Alfaro, R. Rubio Renau, C. Solà, S. Bolea, M. Quindós
Journal: Annals of Oncology (2024)
1631P Results from the quick efficacy seeking trial (QuEST1) arm combining BN-brachyury (BNVax) + bintrafusp alfa (BA) + nogapendekin alfa inbakicept-pmln (N-803) in castration-resistant prostate cancer (CRPC)
Authors: J.M. Redman, R.A. Madan, F. Karzai, L. Cordes, None J. Marte, N. Williams, A. Hankin, N. Toney, R.N. Donahue, S. Steinberg, P. Soon-Shiong, J. Schlom, E. Turkbey, J.L. Gulley
Journal: Annals of Oncology (2024)
1612P Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Authors: D. Lorente, B. Herrera Imbroda, A. Jambrina, D. Tello, N. Romero Laorden, P. Lopez Casas, M. Balongo, M. Ovejero, L. Almalé, N. Vidal Cassinello, M.J. Mendez Vidal, C. Capone, A.M. Vanden Broecke, M. Trevisan, S. Van Sanden, A. Jürgens, E. Gonzalez Billalabeitia, D. Olmos, E. Castro
Journal: Annals of Oncology (2024)
1627P Long survivors after androgen deprivation therapy (ADT) with or without docetaxel for metastatic castration-sensitive prostate cancer (mCSPC): Long-term follow-up of GETUG-15
Authors: S. Blanchet-Deverly, K. Fizazi, S. Oudard, G. Gravis, E. Boughalem, D. Borchiellini, S. Foulon, F. Peyre Pradat, P. Beuzeboc, L. Mourey, B. Laguerre, M. Jacobs, D. Tosi, F. Priou, P. Sfumato, V. Massard
Journal: Annals of Oncology (2024)
1617P Multi-gene copy number variation risk-score for prediction of survival and therapy response outcome in treatment-naïve metastatic castrate resistant prostate cancer
Authors: M. Kohli, D. Nix, C. Herberts, C. Maurice-Dror, A.W. Wyatt, B. Schmidt, B. Fairbourn, A-C. Tan, L. Wang, Z. Wilmot
Journal: Annals of Oncology (2024)
1649P Impact of concomitant medications on safety in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) receiving rezvilutamide (Rez) plus androgen-deprivation therapy (ADT): A post-hoc analysis of the randomized phase III CHART trial
Authors: D. Ye, S. Wang, Z. Wang, N. Xing, W. Yang, Z. Wang, X. Gu, G. Zhou, Z. Sun, J. Guo, X. Xue, Y. Yang, C. Fu, C. Wang, D. Ding, A. Zhang, S. Jiang, X. Yang, J. Lian, W. Wang
Journal: Annals of Oncology (2024)
1602P CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study results
Authors: K. Li, J. Guo, J. Wu, H. Guo, H. Hang, J. Dai, L. Yang, Q. Zhang, S. Ye, Y. Liu, L. Zhou, R. Huang, M. Xu, B. Pan, J. Zhang, Y. Shi, H. Huang
Journal: Annals of Oncology (2024)
1646P A multicohort phase II trial of androgen deprivation therapy (ADT), docetaxel (DOCE) and nivolumab (NIVO) in patients (pts) with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) enriched for inflamed tumours and DNA damage repair (DDR) alterations: Cohort 3 results
Authors: X.X. Wei, J. Chahoud, H. Emamekhoo, R.R. McKay, C.H. Marshall, D. Einstein, J.M. Lang, S. Raymond, D.A. Roberts, P. Ravi, A. Tewari, M. Pomerantz, F. Dong, S. Siegmund, S. Rodig, C. Sweeney, M.E. Taplin
Journal: Annals of Oncology (2024)
1652P SAABR: Single arm phase II study of androgen receptor pathway inhibitor (ARPI) + atezolizumab + GnRH analog (ADT) and stereotactic body radiotherapy (SBRT) to the prostate in men with de novo hormone-sensitive metastatic prostate cancer (mHSPC)
Authors: D. Rathkopf, M. Dallos, M. Stein, C.S. Spina, I. Deutsch, C. Nguyen, A. Okada, M. Lloyd, J. Manarite, S. McBride
Journal: Annals of Oncology (2024)
1630P A multicenter retrospective study on the efficacy of anti-PD-(L)1 in microsatellite unstable (MSI-H) metastatic castrate-resistant prostate cancer (mCRPC)
Authors: S. Van Wilpe, T. Taha, E. Rothmann, E. Altshuler, E. Ledet, A.M. Bergman, P. Tsantoulis, J. Oldenburg, A. Bernard-Tessier, D. Robbrecht, C. Bruijnen, T. Van Der Hulle, E.S. Antonarakis, C.A. Rothermundt, A.G. Omlin, O. Sartor, L. Sena, H. Beltran, J.S. de Bono, N. Mehra
Journal: Annals of Oncology (2024)
1665P Awareness of illness, psychological difficulties, and resources across life ages in early stage and metastatic cancer patients
Authors: R.D.G. Sartori, D. Dalu, V. Biscaldi, M.S. Cona, A. Gambaro, L. Ruggieri, O. Amato, C. Fasola, S. Ferrario, C. Marrazzo, N.M. La Verde
Journal: Annals of Oncology (2024)
1656TiP The STAMPEDE2 niraparib-abiraterone acetate + prednisolone trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) with a deleterious alteration in a homologous recombination repair (HRR) gene starting androgen deprivation therapy (ADT)
Authors: S. Howlett, M. Kayani, L.C. Brown, C.L. Amos, P. Dutey-Magni, Y. Yogeswaran, L. O'Shea, C. Hogan, A. Wingate, S. Lall, R. Eeles, M. Hubank, P. Williams, W. Cross, A. Sachdeva, N. Clarke, M.K. Parmar, N.D. James, E. Grist, G. Attard
Journal: Annals of Oncology (2024)
1648P Final clinical and liquid biopsy (LBx) results of phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)
Authors: J.M. Lang, S.T. Tagawa, S. Slovin, J.M. Sperger, J.L. Schehr, C. Stahlfeld, A.M. Hintz, H. Emamekhoo, D. Rathkopf, W. Abida, K. Autio, H. Xiao, A. Mitchell, A.M. Molina, S.G. Zhao, J. Eickhoff, S. Dehm, D.M. Nanus, C. Kyriakopoulos
Journal: Annals of Oncology (2024)
Altered glycosylation in cancer: molecular functions and therapeutic potential
Authors: Xuemeng Xu, Qiu Peng, Xianjie Jiang, Shiming Tan, Wenjuan Yang, Yaqian Han, Linda Oyang, Jinguan Lin, Mengzhou Shen, Jiewen Wang, Haofan Li, Longzheng Xia, Mingjing Peng, Nayiyuan Wu, Yanyan Tang, Hui Wang, Qianjin Liao, Yujuan Zhou
Journal: Cancer Communications (2024)

Abstract Glycosylation, a key mode of protein modification in living organisms, is critical in regulating various biological functions by influencing protein folding, transportation, and localization. Changes in glycosylation patterns are a significant feature of cancer, are associated with a range of pathological activities in cancer‐related processes, and serve as critical biomarkers providing new targets for cancer diagnosis and treatment. Glycoproteins like human epidermal growth factor receptor 2 (HER2) for breast cancer, alpha‐fetoprotein (AFP) for liver cancer, carcinoembryonic antigen (CEA) for colon cancer, and prostate‐specific antigen (PSA) for prostate cancer are all tumor biomarkers approved for clinical use. Here, we introduce the diversity of glycosylation structures and newly discovered glycosylation substrate—glycosylated RNA (glycoRNA). This article focuses primarily on tumor metastasis, immune evasion, metabolic reprogramming, aberrant ferroptosis responses, and cellular senescence to illustrate the role of glycosylation in cancer. Additionally, we summarize the clinical applications of protein glycosylation in cancer diagnostics, treatment, and multidrug resistance. We envision a promising future for the clinical applications of protein glycosylation.
Spatiotemporal EP4–fibulin-1 expression is associated with vascular intimal hyperplasia
Authors: Shigekuni Okumura, Sayuki Oka, Takako Sasaki, Marion A Cooley, Yuko Hidaka, Hana Inoue, Hitoshi Nishijima, Shin-Ichiro Ohno, Shota Tanifuji, Mari Kaneko, Takaya Abe, Masahiko Kuroda, Tadashi Yokosuka, Richard M Breyer, Hiroshi Homma, Yuko Kato, Utako Yokoyama
Journal: Cardiovascular Research (2024)

Abstract Aims Cyclooxygenase-2–derived prostaglandin E2 (PGE2) is thought to promote vascular intimal hyperplasia (IH). It has been reported that the PGE2 receptor EP4 is upregulated in injured vessels, and that EP4 signaling in vascular smooth muscle cells (VSMCs) promotes IH. In contrast, EP4 in endothelial cells has been demonstrated to restrain IH. We aimed to investigate spatiotemporal expression of EP4 and whether modulating EP4 signaling could be a viable therapeutic strategy. Methods and Results We generated EP4 reporter mice (Ptger4-IRES-nlsLacZ) and found temporary but prominent EP4 expression in VSMCs of the proliferative neointima 2 weeks after femoral artery wire injury. Injury-induced IH was diminished in VSMC-targeted EP4 heterozygous deficient mice (Ptger4fl/+; SM22-Cre) 2 and 4 weeks after vascular injury compared to that in SM22-Cre, whereas injury-induced IH was exacerbated in VSMC-targeted EP4-overexpressing mice (Ptger4-Tg) compared to controls (non-Tg). We then investigated the downstream signaling of EP4 in VSMCs. Stimulation of EP4 increased mRNA and protein levels of the glycoprotein fibulin-1 in Ptger4-Tg VSMCs. Fibulin-1C recombinant proteins increased VSMC proliferation and migration through transforming growth factor (TGF)-β/Smad3, and EP4-mediated proliferation and migration were attenuated in Fbln1fl/fl; SM22-Cre VSMCs and in CRISPR/Cas9-mediated Fbln1 knockdown in Ptger4-Tg VSMCs. We generated multiple deletion mutants of fibulin-1C and found that EGF-like modules 6-8 appear to be involved in fibulin-1–mediated proliferation. Among binding partners of fibulin-1, extracellular matrix protein 1 (ECM1) was also upregulated by EP4 stimulation, and fibulin-1C and ECM1 proteins additively enhanced VSMC proliferation and migration. Injury-induced IH was attenuated in VSMC-targeted fibulin-1 deletion mice (Fbln1fl/fl; SM22-Cre) compared to Fbln1fl/fl. Furthermore, systemic EP4 antagonist administration reduced injury-induced IH in wild-type mice. Conclusions EP4 was upregulated in VSMCs of proliferative IH, and EP4 signaling promoted IH, at least in part through fibulin-1. An EP4 antagonist might be considered as a therapeutic strategy for IH.
A morphologically transformable hypoxia-induced radical anion for tumor-specific photothermal therapy
Authors: Hongyu Wang, Dengyuan Hao, Qihang Wu, Tingting Sun, Zhigang Xie
Journal: Acta Pharmaceutica Sinica B (2024)

Tumor microenvironment activatable therapeutic agents and their effective tumor accumulation are significant for selective tumor treatment. Herein, we provide an unadulterated nanomaterial combining the above advantages. We synthesize a perylene diimide (PDI) molecule substituted by glutamic acid (Glu), which can self-assemble into small spherical nanoparticles (PDI-SG) in aqueous solution. PDI-SG can not only be transformed into nanofibers at low pH conditions but also be reduced to PDI radical anion (PDI·‒), which exhibits strong near-infrared absorption and excellent photothermal performance. More importantly, PDI-SG can also be reduced to PDI·‒ in hypoxic tumors to ablate the tumors and minimize the damage to normal tissues. The morphological transformation from small nanoparticles to nanofibers makes for better tumor accumulation and retention. This work sheds light on the design of tumor microenvironment activatable therapeutics with precise structures for high-performance tumor therapy.
Alkyl chain length-regulated in situ intelligent nano-assemblies with AIE-active photosensitizers for photodynamic cancer therapy
Authors: Lingyi Shen, Qi-Long Zhang, Yongchao Yao, Ya-Li Huang, Zhichang Zheng, Ming Li, Hong Xu, Lin Tan, Xukun Liao, Binyi Xia, Lin Li, Carl Redshaw, Yang Bai, Chengli Yang
Journal: Asian Journal of Pharmaceutical Sciences (2024)

Photodynamic therapy (PDT) brings new hope for the treatment of breast cancer due to few side effects and highly effective cell killing; however, the low bioavailability of traditional photosensitizers (PSs) and their dependence on oxygen severely limits their application. Aggregation-induced emission (AIE) PSs can dramatically facilitate the photosensitization effect, which can have positive impacts on tumor PDT. To-date, most AIE PSs lack tumor targeting capability and possess poor cell delivery, resulting in their use in large quantities that are harmful to healthy tissues. In this study, a series of AIE PSs based on pyridinium-substituted triphenylamine salts ( TTPAs 1-6) with different alkyl chain lengths are synthesized. Results reveal that TTPAs 1-6 promote the generation of type I and II ROS, including ·OH and 1O2. In particular, the membrane permeability and targeting of TTPAs 4-6 bearing C8-C10 side-chains are higher than TTPAs 1-3 bearing shorter alkyl chains. Additionally, they can assemble with albumin, thereby forming nanoparticles (TTPA 4-6 NPs) in situ in blood, which significantly facilitates mitochondrial-targeting and strong ROS generation ability. Moreover, the TTPA 4-6 NPs are pH-responsive, allowing for increased accumulation or endocytosis of the tumor and enhancing the imaging or therapeutic effect. Therefore, the in vivo distributions of TTPA 4-6 NPs are visually enriched in tumor sites and exhibited excellent PDT efficacy. This work demonstrates a novel strategy for AIE PDT and has the potential to play an essential role in clinical applications using nano-delivery systems.
Overexpression of PRDM16 attenuates acute kidney injury progression: genetic and pharmacological approaches
Authors: Xiaozhou Li, Fang Xu, Pan Zhang, Liufeng Mao, Yong Guo, Huiling Li, Yuxing Xie, Yijian Li, Yingjun Liao, Junxiang Chen, Donghai Wu, Dongshan Zhang
Journal: MedComm (2024)

Acute kidney injury (AKI) presents as a condition marked by a sudden and rapid decrease in kidney function over a short timeframe, resulting from diverse causes. As a transcription factor, PR domain-containing 16 (PRDM16), has recently been implicated in brown fat biogenesis and heart diseases. Our recent works indicated that PRDM16 could suppress the occurrence of renal interstitial fibrosis in diabetic kidney disorder. Nonetheless, the effect and regulatory mechanism of PRDM16 in AKI remain elusive. Our study demonstrated that PRDM16 inhibited apoptosis induced by ischemic/reperfusion (I/R) in BUMPT (Boston University mouse kidney proximal tubular) cells and HK-2(Human Kidney-2) cells. Mechanistically, PRDM16 not only bound to the promoter region of S100 Calcium Binding Protein A6 (S100A6)and upregulated its expression but also interacted with its amino acids 945-949, 957-960, and 981-984 to suppress the p38MAPK and JNK axes via inhibition of PKC-η activity and mitochondrial reactive oxygen species (ROS) production. Furthermore, cisplatin- and I/R-stimulated AKI progression were ameliorated in PRDM16 proximal-tubule-specific knockin mice, whereas exacerbated in PRDM16 knockout proximal-tubule-specific mice). Moreover, we observed that formononetin ameliorated I/R- and cisplatin-triggered AKI progression in mice. Taken together, these findings reveal a novel self-protective mechanism in AKI, whereby PRDM16 regulates the S100A6/PKC-η/ROS/p38MAPK and JNK pathways to inhibit AKI progression.
Structure based Release Kinetics Analysis of Doxazosin Mesylate Sustained-Release Tablets Using Micro-Computed Tomography
Authors: Qian Liu, Mengqing Zan, Hanhan Huang, Hai Su, Wenjing Zhang, Lingyun Ma, Guangchao Zhang, Zunjian Zhang, Jiwen Zhang, Jianzhao Niu, Mingdi Xu
Journal: Asian Journal of Pharmaceutical Sciences (2024)

The structures of solid dosage forms determine their release behaviors and are critical attributes for the design and evaluation of the solid dosage forms. Here, the 3D structures of doxazosin mesylate sustained-release tablets were parallelly assessed by micro-computed tomography (micro-CT). There were no significant differences observed in the release profiles between the RLD and the generic formulation in the conventional dissolution, but the generic preparation released slightly faster in media with ethanol during an alcohol-induced dose-dumping test. With their 3D structures obtained via micro-CT determination, the unique release behaviors of both RLD and the generic were investigated to reveal the effects of internal fine structure on the release kinetics. The structural parameters for both preparations were similar in conventional dissolution test, while the dissolutions in ethanol media showed some distinctions between RLD and generic preparations due to their static and dynamic structures. Furthermore, the findings revealed that the presence of ethanol accelerated dissolution and induced changes in internal structure of both RLD and generic preparations. Moreover, structure parameters like volume and area of outer contour, remaining solid volume and cavity volume were not equivalent between the two formulations in 40 % ethanol. In conclusion, the structure data obtained from this study provided valuable insights into the diverse release behaviors observed in various modified-release formulations in drug development and quality control.